|
1
|
Rosamond W, Flegal K, Friday G, Furie K,
Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, et al
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee: Heart- disease and stroke statistics -
2007 update: A report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee.
Circulation. 115:e69–e171. 2007. View Article : Google Scholar
|
|
2
|
Quazi R, Palaniswamy C and Frishman WH:
The emerging role of apelin in cardiovascular disease and health.
Cardiol Rev. 17:283–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH,
Zhao J, Yu F, Duan XH, Tang CS and Qi YF: Apelin activates
L-arginine/nitric oxide synthase/nitric oxide pathway in rat
aortas. Peptides. 28:2023–2029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japp AG and Newby DE: The apelin-APJ
system in heart failure: Pathophysiologic relevance and therapeutic
potential. Biochem Pharmacol. 75:1882–1892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tatemoto K, Takayama K, Zou MX, Kumaki I,
Zhang W, Kumano K and Fujimiya M: The novel peptide apelin lowers
blood pressure via a nitric oxide-dependent mechanism. Regul Pept.
99:87–92. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashley EA, Powers J, Chen M, Kundu R,
Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal
R, et al: The endogenous peptide apelin potently improves cardiac
contractility and reduces cardiac loading in vivo. Cardiovasc Res.
65:73–82. 2005. View Article : Google Scholar
|
|
7
|
Berry MF, Pirolli TJ, Jayasankar V,
Burdick J, Morine KJ, Gardner TJ and Woo YJ: Apelin has in vivo
inotropic effects on normal and failing hearts. Circulation. 110(11
Suppl 1): II187–II193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szokodi I, Tavi P, Földes G,
Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J,
Rysä J, Tóth M and Ruskoaho H: Apelin, the novel endogenous ligand
of the orphan receptor APJ, regulates cardiac contractility. Circ
Res. 91:434–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chandrasekaran B, Dar O and McDonagh T:
The role of apelin in cardiovascular function and heart failure.
Eur J Heart Fail. 10:725–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ
and Tang CS: Apelin protects heart against ischemia/reperfusion
injury in rat. Peptides. 30:1144–1152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao J, Zhu W, Li Y, Xin P, Li J, Liu M, Li
J, Redington AN and Wei M: Apelin-13 protects the heart against
ischemia-reperfusion injury through inhibition of ER-dependent
apoptotic pathways in a time-dependent fashion. Am J Physiol Heart
Circ Physiol. 301:H1471–H1486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barnes G, Japp AG and Newby DE:
Translational promise of the apelin - APJ system. Heart.
96:1011–1016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patten RD, Aronovitz MJ, Deras-Mejia L,
Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME and Konstam MA:
Ventricular remodeling in a mouse model of myocardial infarction.
Am J Physiol. 274:H1812–H1820. 1998.PubMed/NCBI
|
|
14
|
Ahn D, Cheng L, Moon C, Spurgeon H,
Lakatta EG and Talan MI: Induction of myocardial infarcts of a
predictable size and location by branch pattern
probability-assisted coronary ligation in C57BL/6 mice. Am J
Physiol Heart Circ Physiol. 286:H1201–H1207. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jia YX, Pan CS, Zhang J, Geng B, Zhao J,
Gerns H, Yang J, Chang JK, Tang CS and Qi YF: Apelin protects
myocardial injury induced by isoproterenol in rats. Regul Pept.
133:147–154. 2006. View Article : Google Scholar
|
|
16
|
Rastaldo R, Cappello S, Folino A, Berta
GN, Sprio AE, Losano G, Samaja M and Pagliaro P: Apelin-13 limits
infarct size and improves cardiac postischemic mechanical recovery
only if given after ischemia. Am J Physiol Heart Circ Physiol.
300:H2308–H2315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, McKinnie SM, Patel VB, Haddad G,
Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, et al:
Loss of Apelin exacerbates myocardial infarction adverse remodeling
and ischemia-reperfusion injury: Therapeutic potential of synthetic
Apelin analogues. J Am Heart Assoc. 2:e0002492013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Azizi Y, Faghihi M, Imani A, Roghani M and
Nazari A: Post-infarct treatment with [Pyr1]-apelin-13 reduces
myocardial damage through reduction of oxidative injury and nitric
oxide enhancement in the rat model of myocardial infarction.
Peptides. 46:76–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui RR, Mao DA, Yi L, Wang C, Zhang XX,
Xie H, Wu XP, Liao XB, Zhou H, Meng JC, et al: Apelin suppresses
apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt
signaling pathways. Amino Acids. 39:1193–1200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eskew RT Jr, Stromeyer CF III, Picotte CJ
and Kronauer RE: Detection uncertainty and the facilitation of
chromatic detection by luminance contours. J Opt Soc Am A.
8:394–403. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Porter KE and Turner NA: Cardiac
fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther.
123:255–278. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pchejetski D, Foussal C, Alfarano C,
Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH,
Wanecq E, Valet P, et al: Apelin prevents cardiac fibroblast
activation and collagen production through inhibition of
sphingosine kinase 1. Eur Heart J. 33:2360–2369. 2012. View Article : Google Scholar
|
|
23
|
Griendling KK, Tsuda T, Berk BC and
Alexander RW: Angiotensin II stimulation of vascular smooth muscle
cells. Secondary signalling mechanisms. Am J Hypertens. 2:659–665.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kagami S, Border WA, Miller DE and Noble
NA: Angiotensin II stimulates extracellular matrix protein
synthesis through induction of transforming growth factor-beta
expression in rat glomerular mesangial cells. J Clin Invest.
93:2431–2437. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siddiquee K, Hampton J, Khan S, Zadory D,
Gleaves L, Vaughan DE and Smith LH: Apelin protects against
angiotensin II-induced cardiovascular fibrosis and decreases
plasminogen activator inhibitor type-1 production. J Hypertens.
29:724–731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kleinz MJ and Baxter GF: Apelin reduces
myocardial reperfusion injury independently of PI3K/Akt and P70S6
kinase. Regul Pept. 146:271–277. 2008. View Article : Google Scholar
|
|
27
|
Simpkin JC, Yellon DM, Davidson SM, Lim
SY, Wynne AM and Smith CC: Apelin-13 and apelin-36 exhibit direct
cardioprotective activity against ischemia-reperfusion injury.
Basic Res Cardiol. 102:518–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Y, Zhang X, Cui H, Zhang C, Zhu C and
Li L: Apelin-13 protects the brain against ischemia/reperfusion
injury through activating PI3K/Akt and ERK1/2 signaling pathways.
Neurosci Lett. 568:44–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Atluri P, Morine KJ, Liao GP, Panlilio CM,
Berry MF, Hsu VM, Hiesinger W, Cohen JE and Joseph Woo Y: Ischemic
heart failure enhances endogenous myocardial apelin and APJ
receptor expression. Cell Mol Biol Lett. 12:127–138. 2007.
View Article : Google Scholar
|
